$ALXO
ALX ONCOLOGY HOLDINGS INC

2022 Q4 Form 10-Q Financial Statement

#000095017022023237 Filed on November 08, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue $0.00
YoY Change
Gross Profit $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $7.022M $7.299M $6.362M
YoY Change -7.34% 14.73% 42.01%
% of Gross Profit
Research & Development $25.20M $29.38M $18.21M
YoY Change 20.59% 61.32% 241.85%
% of Gross Profit
Depreciation & Amortization $105.0K $95.00K $6.000K
YoY Change 208.82% 1483.33% -40.0%
% of Gross Profit
Operating Expenses $32.22M $36.68M $18.21M
YoY Change 13.16% 101.39% 85.69%
Operating Profit -$36.68M -$18.21M
YoY Change 101.39% 85.69%
Interest Expense $1.807M $1.370M -$4.000K
YoY Change -60333.33% -34350.0% -98.23%
% of Operating Profit
Other Income/Expense, Net -$233.0K -$9.000K $14.00K
YoY Change -1556.25% -164.29% -112.61%
Pretax Income -$30.65M -$35.32M -$24.57M
YoY Change 7.68% 43.78% 142.12%
Income Tax $64.00K $0.00
% Of Pretax Income
Net Earnings -$30.71M -$35.32M -$24.57M
YoY Change 7.99% 43.78% 141.29%
Net Earnings / Revenue
Basic Earnings Per Share -$0.87 -$0.61
Diluted Earnings Per Share -$0.75 -$0.87 -$608.1K
COMMON SHARES
Basic Shares Outstanding 40.76M 40.75M 40.40M
Diluted Shares Outstanding 40.75M 40.40M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $266.2M $284.9M $385.1M
YoY Change -26.8% -26.03% 48.42%
Cash & Equivalents $48.82M $49.05M $385.1M
Short-Term Investments $217.4M $235.9M
Other Short-Term Assets $4.762M $5.899M $3.814M
YoY Change 42.06% 54.67% 58.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $271.0M $290.8M $389.0M
YoY Change -26.17% -25.24% 48.23%
LONG-TERM ASSETS
Property, Plant & Equipment $3.889M $2.336M $562.0K
YoY Change 333.56% 315.66% 1148.89%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $16.70M $8.217M
YoY Change
Other Assets $14.93M $16.33M $10.20M
YoY Change 21.72% 60.03%
Total Long-Term Assets $35.52M $26.88M $10.77M
YoY Change 169.83% 149.71% 23822.22%
TOTAL ASSETS
Total Short-Term Assets $271.0M $290.8M $389.0M
Total Long-Term Assets $35.52M $26.88M $10.77M
Total Assets $306.5M $317.7M $399.7M
YoY Change -19.38% -20.52% 52.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.073M $5.880M $3.683M
YoY Change 114.48% 59.65% 159.18%
Accrued Expenses $19.79M $18.97M $8.376M
YoY Change 78.27% 126.48% 222.15%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $393.0K $429.0K
YoY Change -100.0% -8.39% -83.31%
Total Short-Term Liabilities $28.33M $25.24M $12.49M
YoY Change 85.19% 102.14% 73.52%
LONG-TERM LIABILITIES
Long-Term Debt $9.389M $0.00 $385.0K
YoY Change 3253.21% -100.0% -87.93%
Other Long-Term Liabilities $5.311M $5.483M $2.068M
YoY Change 188.8% 165.14% 4300.0%
Total Long-Term Liabilities $14.70M $5.483M $2.068M
YoY Change 699.35% 165.14% -36.09%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.33M $25.24M $12.49M
Total Long-Term Liabilities $14.70M $5.483M $2.068M
Total Liabilities $43.03M $30.73M $14.56M
YoY Change 151.11% 111.09% 39.52%
SHAREHOLDERS EQUITY
Retained Earnings -$325.5M -$294.8M -$173.5M
YoY Change 61.13% 69.84%
Common Stock $589.8M $583.2M $558.7M
YoY Change 4.38% 4.39%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $263.5M $287.0M $385.2M
YoY Change
Total Liabilities & Shareholders Equity $306.5M $317.7M $399.7M
YoY Change -19.38% -20.52% 52.34%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$30.71M -$35.32M -$24.57M
YoY Change 7.99% 43.78% 141.29%
Depreciation, Depletion And Amortization $105.0K $95.00K $6.000K
YoY Change 208.82% 1483.33% -40.0%
Cash From Operating Activities -$20.67M -$30.88M -$24.86M
YoY Change 18.18% 24.25% 160.55%
INVESTING ACTIVITIES
Capital Expenditures $389.0K -$192.0K -$398.0K
YoY Change -108.61% -51.76% 3880.0%
Acquisitions
YoY Change
Other Investing Activities $11.33M $13.89M $0.00
YoY Change -100.0%
Cash From Investing Activities $10.94M $13.69M -$398.0K
YoY Change -342.19% -3540.95% -163.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.494M -136.0K 439.0K
YoY Change 1711.83% -130.98% -99.74%
NET CHANGE
Cash From Operating Activities -20.67M -30.88M -24.86M
Cash From Investing Activities 10.94M 13.69M -398.0K
Cash From Financing Activities 9.494M -136.0K 439.0K
Net Change In Cash -232.0K -17.32M -24.81M
YoY Change -98.92% -30.19% -115.38%
FREE CASH FLOW
Cash From Operating Activities -$20.67M -$30.88M -$24.86M
Capital Expenditures $389.0K -$192.0K -$398.0K
Free Cash Flow -$21.06M -$30.69M -$24.46M
YoY Change 62.35% 25.48% 156.64%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-314547000
dei Entity Central Index Key
EntityCentralIndexKey
0001810182
dei Amendment Flag
AmendmentFlag
false
dei Entity Small Business
EntitySmallBusiness
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss Statement Of Financial Position Extensible List
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLossStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#PrepaidExpenseAndOtherAssetsCurrent
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40755452
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49054000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
363667000
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39386
dei Entity Registrant Name
EntityRegistrantName
ALX ONCOLOGY HOLDINGS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-0642577
dei Entity Address Address Line1
EntityAddressAddressLine1
323 Allerton Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
466-7125
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
ALXO
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
235855000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5899000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3352000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
290808000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
367019000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2336000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
897000
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
8217000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16328000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12267000
CY2022Q3 us-gaap Assets
Assets
317689000
CY2021Q4 us-gaap Assets
Assets
380183000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
5880000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3764000
CY2022Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
2759000
CY2021Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1630000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16604000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9901000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
25243000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15295000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5483000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1839000
CY2022Q3 us-gaap Liabilities
Liabilities
30726000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
380183000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
29382000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18214000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73203000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2021Q4 us-gaap Liabilities
Liabilities
17134000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40748290
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40748290
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40587067
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40587067
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
41000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
41000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
583184000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
564993000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1504000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-294758000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-201985000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
286963000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
363049000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
317689000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
39276000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7299000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6362000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22014000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15807000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
36681000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
24576000
us-gaap Operating Expenses
OperatingExpenses
95217000
us-gaap Operating Expenses
OperatingExpenses
55083000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-36681000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-24576000
us-gaap Operating Income Loss
OperatingIncomeLoss
-95217000
us-gaap Operating Income Loss
OperatingIncomeLoss
-55083000
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1370000
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
22000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
2471000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
70000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-27000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35320000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24566000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
us-gaap Net Income Loss
NetIncomeLoss
-55025000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-248000
us-gaap Net Income Loss
NetIncomeLoss
-92773000
us-gaap Net Income Loss
NetIncomeLoss
-55025000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40747026
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40747026
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40396188
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40396188
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40684172
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40684172
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40234159
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40234159
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35320000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24566000
us-gaap Net Income Loss
NetIncomeLoss
-92773000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1504000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35568000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-24566000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-94277000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-55025000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
363049000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
185000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5501000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-606000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-24533000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
343596000
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
155000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
302000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5836000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-650000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-32920000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
316319000
CY2022Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6207000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-248000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35320000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
286963000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
429845000
CY2021Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1024000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2042000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1800000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-14185000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
418484000
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
464000
CY2021Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
103000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2237000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-16274000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
405014000
CY2021Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
533000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4191000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24566000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
385172000
us-gaap Profit Loss
ProfitLoss
-92773000
us-gaap Profit Loss
ProfitLoss
-55025000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
237000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17000
alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
816000
alxo Operating Finance Lease Right Of Use Asset Amortization Expense
OperatingFinanceLeaseRightOfUseAssetAmortizationExpense
460000
us-gaap Share Based Compensation
ShareBasedCompensation
17544000
us-gaap Share Based Compensation
ShareBasedCompensation
8228000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
256000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2613000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
267000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
10653000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2052000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3620000
alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
1129000
alxo Increase Decrease In Payable And Accrued Liabilities Due To Related Parties Current
IncreaseDecreaseInPayableAndAccruedLiabilitiesDueToRelatedPartiesCurrent
386000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
6412000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
2333000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-836000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
2063000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68555000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-50613000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
315820000
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
70500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1038000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
405000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-246358000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-405000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
345000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2022000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
302000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
103000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
281000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
177000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
366000
CY2022Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
410000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
385149000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1948000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2636000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
960000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
300000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-49070000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
363667000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
434219000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49120000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
385149000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
876000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
129000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4684000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1812000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
834000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49054000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
385149000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
66000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
49120000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Reclassifications</span></p><p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Certain amounts in the prior period have been reclassified to conform to the current period presentation.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. On an ongoing basis, management evaluates its estimates, including those related to the estimated useful lives of long-lived assets, clinical trial accruals, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></p>
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
63000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2336000
CY2022Q3 alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
283344000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
357181000
CY2022Q3 us-gaap Cash
Cash
9800000
CY2021Q4 us-gaap Cash
Cash
6500000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
275126000
CY2021Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
357181000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
8218000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
283344000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
357181000
alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
CY2021Q3 alxo Fair Value Assets And Liabilities Transfers Amount
FairValueAssetsAndLiabilitiesTransfersAmount
0
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
897000
CY2022Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
400000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
297000
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2021Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
0
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5893000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1829000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2022Q3 us-gaap Debt Securities Available For Sale Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAccruedInterestAfterAllowanceForCreditLoss
700000
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2022Q3 us-gaap Impairment Of Investments
ImpairmentOfInvestments
0
CY2021Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
746000
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
144000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
144000
CY2022Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
66000
CY2022Q3 us-gaap Interest Receivable Noncurrent
InterestReceivableNoncurrent
48000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16328000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
12267000
CY2022Q3 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
5477000
CY2021Q4 alxo Accrued Contract Manufacturing Current
AccruedContractManufacturingCurrent
693000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4849000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3294000
CY2022Q3 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
3698000
CY2021Q4 alxo Accrued Clinical And Non Clinical Costs Current
AccruedClinicalAndNonClinicalCostsCurrent
4125000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
724000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
313000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
571000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
790000
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
393000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
429000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
892000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
257000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
16604000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
9901000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5900000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6223000
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
393000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y6M
CY2022Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
108000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
1246000
CY2022Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P0Y10M24D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.084
CY2022Q3 us-gaap Finance Lease Liability Payments Due In Next Rolling Twelve Months
FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths
288000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
1273000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4684000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1812000
CY2022Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.017
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
1311000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
1193000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
3000000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8320000
CY2022Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
396000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2097000
CY2022Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
3000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
6223000
CY2022Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
393000
CY2022Q3 alxo Operating Lease Liability Current Including Payable And Accrued Liabilities Due To Related Party
OperatingLeaseLiabilityCurrentIncludingPayableAndAccruedLiabilitiesDueToRelatedParty
740000
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
393000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5483000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
320000
CY2021Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
132000
us-gaap Operating Lease Cost
OperatingLeaseCost
840000
us-gaap Operating Lease Cost
OperatingLeaseCost
229000
CY2022Q3 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
60000
CY2021Q3 alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
22000
alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
203000
alxo Variable Lease Cost And Other Net
VariableLeaseCostAndOtherNet
61000
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
3000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
86000
CY2022Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
112000
CY2021Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
112000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
336000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
257000
CY2022Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
2000
CY2021Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
7000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
10000
CY2022Q3 us-gaap Lease Cost
LeaseCost
497000
CY2021Q3 us-gaap Lease Cost
LeaseCost
269000
us-gaap Lease Cost
LeaseCost
1472000
us-gaap Lease Cost
LeaseCost
557000
us-gaap Operating Lease Payments
OperatingLeasePayments
681000
us-gaap Operating Lease Payments
OperatingLeasePayments
141000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
7000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
7000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
281000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
177000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
834000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40748290
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40587067
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11210565
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6207000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4191000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17544000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8228000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35320000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-24566000
us-gaap Net Income Loss
NetIncomeLoss
-92773000
us-gaap Net Income Loss
NetIncomeLoss
-55025000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40747026
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40747026
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40396188
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40396188
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40684172
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40684172
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40234159
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40234159
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.87
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.87
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.61
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.61
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.28
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7106281
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4909185
CY2022Q3 alxo Number Of Pending Or Threatened Litigation
NumberOfPendingOrThreatenedLitigation
0

Files In Submission

Name View Source Status
0000950170-22-023237-index-headers.html Edgar Link pending
0000950170-22-023237-index.html Edgar Link pending
0000950170-22-023237.txt Edgar Link pending
0000950170-22-023237-xbrl.zip Edgar Link pending
alxo-20220930.htm Edgar Link pending
alxo-20220930.xsd Edgar Link pending
alxo-ex31_1.htm Edgar Link pending
alxo-ex31_2.htm Edgar Link pending
alxo-ex32_1.htm Edgar Link pending
alxo-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
alxo-20220930_cal.xml Edgar Link unprocessable
alxo-20220930_def.xml Edgar Link unprocessable
alxo-20220930_lab.xml Edgar Link unprocessable
alxo-20220930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
alxo-20220930_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending